Continue monitoring. No immediate action required.
Note: SpO2 monitoring is supplementary screening and cannot substitute for pulmonary function testing (spirometry). Normal SpO2 does not exclude early-stage BOS (bronchiolitis obliterans syndrome).
Slope: 0.00100%/day (+0.030%/month). 95% CI: [-0.00289, 0.00489]. p=0.6098.
Prediction:
| Time Horizon | Predicted SpO2 | 95% PI |
|---|---|---|
| 30d | 96.2% | [94.8, 97.6]% |
| 60d | 96.2% | [94.8, 97.7]% |
| 90d | 96.3% | [94.8, 97.8]% |
Concern Level: LOW
Absolute threshold (<94%): 1 nights (1.1%)
Relative threshold (<95.56%, baseline-2SD): 15 nights (15.8%)
Frequency trend: First half: 0.0% vs second half: 2.1% - INCREASING FREQUENCY
Overall SD: 0.679% | CV: 0.706%
Night-to-night difference SD: 0.825%
First half SD: 0.574% vs second half: 0.768% - INCREASING VARIABILITY
Pearson r: -0.1938 (p=0.047582)
Spearman rho: -0.1563 (p=0.111419)
Status: WEAK (possible decoupling)
Interpretation: Weak inverse coupling suggests a blunted compensatory response.
Normal: Inverse relationship (SpO2 down -> HR up, compensatory). Decoupling (positive or zero correlation) = autonomic dysfunction or respiratory failure.
DLCO Measurements:
| Date | DLCO% | Context | Concurrent SpO2 |
|---|---|---|---|
| 2024-03-21 | 71% | Baseline post-HSCT | No data |
| 2025-03-20 | 89% | Improvement | No data |
| 2025-12-17 | 67% | Concerning decline | No data |
DLCO Trajectory: 71% (Baseline post-HSCT) -> 89% (Improvement) -> 67% (Concerning decline)
SpO2 monitoring started after the last DLCO measurement. Direct correlation not possible, but trend direction is consistent with DLCO decline.
Mean BDI: 5.13 events/hour (status: MILD ELEVATION)
Elevated nights (>=5): 49 of 95 (51.6%)
BDI trend: slope=-0.0023/day (p=0.825537)
Pearson r: -0.1354 (p=0.190718)
Interpretation: Weak coupling: SpO2 relatively independent of temperature
Composite Score: 13/100 - LOW
| Component | Score | Weight | Contribution |
|---|---|---|---|
| SpO2 Trend | 0/100 | 30% | 0.0 |
| SpO2 Variability | 21/100 | 20% | 4.1 |
| Desaturation Frequency | 9/100 | 20% | 1.8 |
| Breathing Disturbance Index (BDI) | 30/100 | 15% | 4.6 |
| HR Decoupling | 18/100 | 15% | 2.7 |
Pre-ruxolitinib (55 nights): 96.079% (SD: 0.569%)
Post-ruxolitinib (40 nights): 96.194%
Status: No statistically significant change after ruxolitinib (yet)
Mann-Whitney U: 971.5 (p=0.334618), effect size (rbc)=0.1168